These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 189042)

  • 1. Vesicular stomatitis virus-infected L1210 murine leukemia cells: increased immunogenicity and altered surface antigens.
    Wise KS
    J Natl Cancer Inst; 1977 Jan; 58(1):83-90. PubMed ID: 189042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common leukemia-associated antigen of DBA/2 mouse leukemia detected by tumor rejection and complement-dependent cytotoxicity assays.
    Kawashima K; Takeyama H; Takahashi T; Kato Y; Watanabe E; Suzuki H; Minam S; Isobe K; Yamada K; Ito Y
    Gan; 1979 Dec; 70(6):769-76. PubMed ID: 94022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay.
    Fuji H; Mihich E
    Cancer Res; 1975 Apr; 35(4):946-52. PubMed ID: 1090366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of vesicular stomatitis virus with murine cell surface antigens.
    Hecht TT; Summers DF
    J Virol; 1976 Sep; 19(3):833-45. PubMed ID: 61285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of tumor resistance in mice by L1210 leukemia cells persistently infected with HVJ (Sendai virus).
    Takeyama H; Kawashima K; Yamada K; Ito Y
    Gan; 1979 Aug; 70(4):493-501. PubMed ID: 229053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental vesicular stomatitis virus infection of swine: extent of infection and immunological response.
    Redelman D; Nichol S; Klieforth R; Van Der Maaten M; Whetstone C
    Vet Immunol Immunopathol; 1989 Mar; 20(4):345-61. PubMed ID: 2470190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SV40 tumor rejection induced by vesicular stomatitis virus bearing SV40 tumor-specific transplantation antigen (SV40-TSTA). I. Specificity of immunoprotection and effect of enzyme treatment on TSTA activity.
    Ansel S; Huet C; Tournier P
    Int J Cancer; 1977 Jul; 20(1):51-60. PubMed ID: 71274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target antigens for H-2-restricted vesicular stomatitis virus-specific cytotoxic T cells.
    Zinkernagel RM; Althage A; Holland J
    J Immunol; 1978 Aug; 121(2):744-8. PubMed ID: 210232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous development of humoral and cellular tumor-specific immunity against L1210 mouse leukemia.
    Kawashima K; Isobe K; Nagase F; Yokochi T; Nagura E; Hasegawa Y; Morishita H; Yamada K; Nakashima I
    Leuk Res; 1985; 9(7):935-9. PubMed ID: 4021540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A.
    Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y
    Cancer Res; 1977 Apr; 37(4):964-8. PubMed ID: 403001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of vesicular stomatitis virus infection on the histocompatibility antigen of L cells.
    Hecht TT; Summers DF
    J Virol; 1972 Oct; 10(4):578-85. PubMed ID: 4343540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H
    Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented immunogenicity of tumor cell membranes produced by surface budding viruses: parameters of optimal immunization.
    Gillette RW; Boone CW
    Int J Cancer; 1976 Aug; 18(2):216-22. PubMed ID: 182646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential tumor immunogenicity of L1210 and its sublines. I. Effect of an increased antigen density on tumor cell surfaces on primary B cell responses in vitro.
    Fuji H; Mihich E; Pressman D
    J Immunol; 1977 Sep; 119(3):983-6. PubMed ID: 330761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A significant role of proximity of HVJ-antigen in the generation of tumor immunity.
    Kawashima K; Watanabe E; Kato Y; Suzuki H; Minami S; Isobe K; Ogura M; Nagura E; Yamada K
    Gan; 1981 Dec; 72(6):955-8. PubMed ID: 6281118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limitation of VSV infection by the host's response to VSV-associated cellular antigens.
    Hecht TT; Paul WE
    J Immunol; 1982 Oct; 129(4):1736-41. PubMed ID: 6180021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The production of vesicular stomatitis virus by antigen- or mitogen-stimulated lymphocytes and continuous lymphoblastoid lines.
    Nowakowski M; Feldman JD; Kano S; Bloom BR
    J Exp Med; 1973 Apr; 137(4):1042-59. PubMed ID: 4348276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytolytic T lymphocytes from the BALB/c-H-2dm2 mouse recognize the vesicular stomatitis virus glycoprotein and are restricted by class II MHC antigens.
    Browning MJ; Huang AS; Reiss CS
    J Immunol; 1990 Aug; 145(3):985-94. PubMed ID: 1695651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N protein is the predominant antigen recognized by vesicular stomatitis virus-specific cytotoxic T cells.
    Puddington L; Bevan MJ; Rose JK; Lefrançois L
    J Virol; 1986 Nov; 60(2):708-17. PubMed ID: 3022003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.